Publicaciones

Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance.

Barone G, Barry A, Bautista F, Brichard B, Defachelles AS, Herd F, Manzitti C, Reinhardt D, Rubio PM, Wieczorek A, van Noesel MM.

 Paediatr Drugs. 2021 Nov;23(6):537-548. doi: 10.1007/s40272-021-00469-9. Epub 2021 Sep 20. PMID: 34541620; PMCID:PMC8563639. 10.1007/s40272-021-00469

https://doi.org/10.1007/s40272-021-00469-9.

MIBG Therapy for Neuroblastoma: Precision Achieved With Dosimetry, and Concern for False Responders.

Rubio PM, Galán V, Rodado S, Plaza D, Martínez L.

Front Med (Lausanne). 2020 May 28;7:173. doi: 10.3389/fmed.2020.00173. PMID: 32549040; PMCID: PMC7270400.  10.3389/fmed.2020.00173 https://doi.org/10.3389/fmed.2020.00173

European Neuroblastoma Study Group and the Children's Cancer and Leukaemia Group (CCLG) (formerly UKCCSG). Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial.

Moreno L, Vaidya SJ, Schrey D, Pinkerton CR, Lewis IJ, Kearns PR, Machin D, Pearson ADJ
Pediatr
Blood Cancer. 2019 Apr;66(4):e27565. doi: 10.1002/pbc.27565. Epub 2018 Dec 5.
PMID: 30516328.

International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN). Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study.

Holmes K, Pötschger U, Pearson ADJ, Sarnacki S, Cecchetto G, Gomez-Chacon J, Squire R, Freud E, Bysiek A, Matthyssens LE, Metzelder M, Monclair T, Stenman J, Rygl M, Rasmussen L, Joseph JM, Irtan S, Avanzini S, Godzinski J, Björnland K, Elliott M, Luksch R, Castel V, Ash S, Balwierz W, Laureys G, Ruud E, Papadakis V, Malis J, Owens C, Schroeder H, Beck-Popovic M, Trahair T, Forjaz de Lacerda A, Ambros PF, Gaze MN, McHugh K, Valteau-Couanet D, Ladenstein RL
J Clin Oncol. 2020 Sep
1;38(25):2902-2915. doi: 10.1200/JCO.19.03117. Epub 2020 Jul 8. PMID: 32639845.

MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients.

Olivera GG, Yáñez Y, Gargallo P, Sendra L, Aliño SF, Segura V, Sanz MÁ, Cañete A, Castel V, Font De Mora J, Hervás D, Berlanga P, Herrero MJ.
Int J Mol Sci.
2020 Apr 14;21(8):2714. doi: 10.3390/ijms21082714. PMID: 32295184; PMCID:
PMC7215604.

Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study.

Morini M, Cangelosi D, Segalerba D, Marimpietri D, Raggi F, Castellano A, Fruci D, de Mora JF, Cañete A, Yáñez Y, Viprey V, Corrias MV, Carlini B, Pezzolo A, Schleiermacher G, Mazzocco K, Ladenstein R, Sementa AR, Conte M, Garaventa A, Burchill S, Luksch R, Bosco MC, Eva A, Varesio L.
Cancers (Basel). 2019 Sep 30;11(10):1476. doi: 10.3390/cancers11101476.
PMID: 31575060; PMCID: PMC6826693.

Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.

Berlanga P, Pasqualini C, Pötschger U, Sangüesa C, Castellani MR, Cañete A, Luksch R, Elliot M, Schreier G, Kropf M, Morgenstern D, Papadakis V, Ash S, Ruud E, Brock P, Wieczorek A, Kogner P, Trahair T, Ambros P, Boterberg T, Castel V, Valteau-Couanet D, Ladenstein R.
Eur J Cancer. 2021
Feb;144:1-8. doi: 10.1016/j.ejca.2020.10.020. Epub 2020 Dec 11. PMID: 33316634.

Distribution of segmental chromosomal alterations in neuroblastoma.

Juan Ribelles A, Gargallo P, Ferriol C, Segura V, Yáñez Y, Juan B, Cañada AJ, Font de Mora J, Cañete A, Castel V.
Clin Transl Oncol. 2020 Sep 18. doi:
10.1007/s12094-020-02497-2. Epub ahead of print. PMID: 32948984.

A Confidence Habitats Methodology in MR Quantitative Diffusion for the Classification of Neuroblastic Tumors.

Cerdá Alberich L, Sangüesa Nebot C, Alberich-Bayarri A, Carot Sierra JM, Martínez de Las Heras B, Veiga Canuto D, Cañete A, Martí-Bonmatí L.
Cancers (Basel). 2020 Dec 21;12(12):3858. doi:
10.3390/cancers12123858. PMID: 33371218; PMCID: PMC7767170.
1 / 5
 
Grupo miembro de:
Con el patrocinio de: